Introgen Therapeutics, which filed for bankruptcy protection late last year, is getting a second shot at life, of sorts.
Houston investors have purchased the company's manufacturing-related assets, reports the Houston Business Journal, and from them formed contract manufacturer Vivante GMP Solutions. At bankruptcy, the Introgen assets were divided into three: manufacturing patents, therapeutic drug assets, and manufacturing-related assets. The investors took advantage of the latter, which include a facility and documentation required to manufacture third-party biologic drugs and clinical trials.
Vivante's focus is biologics for academic institutions and biotech companies. According to the press report, several biotechs have engaged the CMO, and it retained customers throughout the bankruptcy, as an Introgen subsidiary.
- see the article [1]
Related Articles:
Bankrupt Introgen operations revived as CMO [2]
Introgen files for Chapter 11, marketing drug portfolio [3]
Small biotechs outline harsh spending cuts [4]
Introgen 'explores options' after troubled Q3 [5]
Introgen shares plunge on BLA rejection [6]
Links:
[1] http://houston.bizjournals.com/houston/stories/2009/09/28/story1.html?surround=etf&ana=e_article&b=1254110400%5e2159651
[2] http://www.fiercebiotech.com/story/bankrupt-introgen-operations-revived-cmo/2009-09-25
[3] http://www.fiercebiotech.com/story/introgen-files-chapter-11-marketing-drug-portfolio/2008-12-04
[4] http://www.fiercebiotech.com/story/small-biotechs-outline-harsh-spending-cuts/2008-12-01
[5] http://www.fiercebiotech.com/story/introgen-considering-options-after-troubled-q3/2008-11-12
[6] http://www.fiercebiotech.com/story/introgen-shares-plunge-news-bla-rejection/2008-09-02